California State Teachers Retirement System Jounce Therapeutics, Inc. Transaction History

California State Teachers Retirement System

$84.1 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$0.9 - $1.85 $1,040 - $2,138	-1,156 Reduced 6.87%	15,666 $28,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $121 - $378	190 Added 1.14%	16,822 $18,000
Q3 2022 Nov 18, 2022	SELL	$2.73 - $4.92 $3,786 - $6,824	-1,387 Reduced 7.7%	16,632 $39,000
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $10,987 - $30,097	3,924 Added 27.84%	18,019 $55,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $22,243 - $31,606	-3,701 Reduced 20.8%	14,095 $96,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $139,582 - $241,777	-27,695 Reduced 60.88%	17,796 $132,000
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $127,336 - $206,292	19,352 Added 74.03%	45,491 $309,000
Q3 2020 Nov 17, 2020	BUY	$4.58 - $10.95 $7,089 - $16,950	1,548 Added 6.29%	26,139 $213,000
Q1 2020 May 13, 2020	BUY	$2.91 - $8.7 $40 - $121	14 Added 0.06%	24,591 $117,000
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $427 - $1,399	152 Added 0.62%	24,577 $215,000
Q1 2019 May 09, 2019	SELL	$3.43 - $6.87 $23,646 - $47,361	-6,894 Reduced 22.01%	24,425 $151,000
Q4 2018 Feb 13, 2019	BUY	$2.69 - $6.71 $19,341 - $48,244	7,190 Added 29.8%	31,319 $106,000
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $12,758 - $38,399	1,755 Added 7.84%	24,129 $185,000
Q1 2018 May 15, 2018	SELL	$13.4 - $28.4 $8,388 - $17,778	-626 Reduced 2.72%	22,374 $500,000
Q4 2017 Feb 14, 2018	SELL	$12.52 - $17.82 $6,260 - $8,910	-500 Reduced 2.13%	23,000 $293,000
Q3 2017 Nov 13, 2017	BUY	$11.17 - $16.99 $262,495 - $399,264	23,500	23,500 $366,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.

Account